(LEGN) Legend Biotech - Ratings and Ratios
CAR-T, Oncology, Myeloma, Hematologic Malignancies, Solid Tumors
LEGN EPS (Earnings per Share)
LEGN Revenue
Description: LEGN Legend Biotech November 05, 2025
Legend Biotech Corp (NASDAQ: LEGN) is a U.S.-based biopharma that discovers, develops, manufactures, and commercializes novel cell-therapy platforms across the United States, China, and Europe. Founded in 2014 and headquartered in Somerset, New Jersey, the firm operates primarily in the biotechnology sub-industry.
The company’s flagship asset is ciltacabtagene autoleucel (cilta-cel), a BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. Cilta-cel received FDA approval in February 2023 and has since generated $85 million in net product revenue in Q1 2024, reflecting early commercial traction in the U.S. market.
Legend’s pipeline extends beyond cilta-cel to include autologous CAR-T candidates for non-Hodgkin lymphoma, acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, hepatocellular, small-cell lung, and non-small-cell lung cancers. In parallel, the firm is advancing allogeneic gamma-delta CAR-T and CAR-NK programs targeting BCMA in Phase 1 investigator-initiated trials in China. Strategic partnerships amplify development and commercialization reach: a collaboration with Janssen Biotech on cilta-cel and a licensing deal with Novartis for delta-like ligand 3-targeted CAR-T therapies.
From a market perspective, the global CAR-T sector is projected to grow at a compound annual growth rate of roughly 20 % through 2030, driven by expanding indications and reimbursement pathways; multiple myeloma alone represents a $13 billion addressable market in the U.S. As of the latest filing, Legend holds approximately $310 million in cash and short-term investments, providing runway for continued R&D and potential geographic expansion. For a deeper, data-driven valuation of LEG N, the ValueRay platform offers granular cash-flow models and scenario analysis you can explore at your own pace.
LEGN Stock Overview
| Market Cap in USD | 6,074m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-06-05 |
LEGN Stock Ratings
| Growth Rating | -38.5% |
| Fundamental | 32.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -38.7% |
| Analyst Rating | 4.45 of 5 |
LEGN Dividends
Currently no dividends paidLEGN Growth Ratios
| Growth Correlation 3m | -89.6% |
| Growth Correlation 12m | -33.9% |
| Growth Correlation 5y | 11.3% |
| CAGR 5y | -14.48% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.23 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.47 |
| Sharpe Ratio 12m | -1.41 |
| Alpha | -36.74 |
| Beta | 0.233 |
| Volatility | 41.27% |
| Current Volume | 824.8k |
| Average Volume 20d | 1257.6k |
| Stop Loss | 30.7 (-4.2%) |
| Signal | 0.06 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-325.8m TTM) > 0 and > 6% of Revenue (6% = 47.9m TTM) |
| FCFTA -0.17 (>2.0%) and ΔFCFTA -6.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 123.4% (prev 247.9%; Δ -124.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -274.7m > Net Income -325.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (92.1m) change vs 12m ago 0.84% (target <= -2.0% for YES) |
| Gross Margin 61.77% (prev 57.85%; Δ 3.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.74% (prev 25.36%; Δ 20.38pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.54 (EBITDA TTM -260.4m / Interest Expense TTM 21.0m) >= 6 (WARN >= 3) |
Altman Z'' -3.98
| (A) 0.58 = (Total Current Assets 1.25b - Total Current Liabilities 265.5m) / Total Assets 1.69b |
| (B) -1.12 = Retained Earnings (Balance) -1.89b / Total Assets 1.69b |
| warn (B) unusual magnitude: -1.12 — check mapping/units |
| (C) -0.16 = EBIT TTM -283.8m / Avg Total Assets 1.74b |
| (D) -2.92 = Book Value of Equity -1.89b / Total Liabilities 647.5m |
| Total Rating: -3.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.24
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -5.28% = -2.64 |
| 3. FCF Margin -36.40% = -7.50 |
| 4. Debt/Equity 0.37 = 2.43 |
| 5. Debt/Ebitda -0.47 = -2.50 |
| 6. ROIC - WACC (= -27.57)% = -12.50 |
| 7. RoE -30.95% = -2.50 |
| 8. Rev. Trend 95.92% = 7.19 |
| 9. EPS Trend 65.23% = 3.26 |
What is the price of LEGN shares?
Over the past week, the price has changed by -1.60%, over one month by +1.94%, over three months by -16.64% and over the past year by -26.51%.
Is Legend Biotech a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LEGN is around 28.35 USD . This means that LEGN is currently overvalued and has a potential downside of -11.54%.
Is LEGN a buy, sell or hold?
- Strong Buy: 11
- Buy: 10
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LEGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 75.1 | 134.2% |
| Analysts Target Price | 75.1 | 134.2% |
| ValueRay Target Price | 31.1 | -3.1% |
LEGN Fundamental Data Overview October 22, 2025
P/E Forward = 19.4553
P/S = 7.6229
P/B = 5.7553
Beta = 0.233
Revenue TTM = 797.7m USD
EBIT TTM = -283.8m USD
EBITDA TTM = -260.4m USD
Long Term Debt = 310.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.91m USD (from shortTermDebt, last quarter)
Debt = 387.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 121.3m USD (from netDebt column, last quarter)
Enterprise Value = 5.49b USD (6.07b + Debt 387.9m - CCE 967.6m)
Interest Coverage Ratio = -13.54 (Ebit TTM -283.8m / Interest Expense TTM 21.0m)
FCF Yield = -5.28% (FCF TTM -290.4m / Enterprise Value 5.49b)
FCF Margin = -36.40% (FCF TTM -290.4m / Revenue TTM 797.7m)
Net Margin = -40.84% (Net Income TTM -325.8m / Revenue TTM 797.7m)
Gross Margin = 61.77% ((Revenue TTM 797.7m - Cost of Revenue TTM 304.9m) / Revenue TTM)
Gross Margin QoQ = 59.29% (prev 63.42%)
Tobins Q-Ratio = 3.25 (Enterprise Value 5.49b / Total Assets 1.69b)
Interest Expense / Debt = 1.35% (Interest Expense 5.24m / Debt 387.9m)
Taxrate = -0.47% (negative due to tax credits) (584.0k / -125.2m)
NOPAT = -285.1m (EBIT -283.8m * (1 - -0.47%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.71 (Total Current Assets 1.25b / Total Current Liabilities 265.5m)
Debt / Equity = 0.37 (Debt 387.9m / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = -0.47 (negative EBITDA) (Net Debt 121.3m / EBITDA -260.4m)
Debt / FCF = -0.42 (negative FCF - burning cash) (Net Debt 121.3m / FCF TTM -290.4m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.28% (Net Income -325.8m / Total Assets 1.69b)
RoE = -30.95% (Net Income TTM -325.8m / Total Stockholder Equity 1.05b)
RoCE = -20.82% (EBIT -283.8m / Capital Employed (Equity 1.05b + L.T.Debt 310.3m))
RoIC = -21.03% (negative operating profit) (NOPAT -285.1m / Invested Capital 1.36b)
WACC = 6.54% (E(6.07b)/V(6.46b) * Re(6.87%) + D(387.9m)/V(6.46b) * Rd(1.35%) * (1-Tc(-0.00)))
Discount Rate = 6.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.61%
Fair Price DCF = unknown (Cash Flow -290.4m)
EPS Correlation: 65.23 | EPS CAGR: 30.95% | SUE: 0.12 | # QB: 0
Revenue Correlation: 95.92 | Revenue CAGR: 125.5% | SUE: -0.79 | # QB: 0
Additional Sources for LEGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle